*Invitation Only – Please contact Lori@califesciences.org for more information.
Proactively understanding the implications of your regulatory pathway, identifying opportunities to engage early and productively with FDA, and developing your product with your reimbursement model in mind can directly influence your development costs, speed to market, and commercial potential. In other words, these are critical drivers for getting your innovative technology to market successfully and efficiently.
The Bioproduction Summit brings you highly technical content focusing on the key challenge areas of biopharmaceutical development. Here you’ll find solutions to the most critical challenges in R&D, upstream, downstream and manufacturing excellence.
Redefining Early Stage Investments (RESI) Conference will join the JPM fray again to connect innovative life science start-ups with active early-stage investors.
An estimated 1.6 million Americans suffer from Inflammatory Bowel Disease (IBD), an umbrella term for two distinct conditions – Crohn’s disease and ulcerative colitis – both characterized by chronic inflammation of the gastrointestinal tract. IBD can significantly affect a patient’s quality of life and may impose tremendous public health burdens, including economic costs. There is … Continue reading Enhancing Patient Access to Therapies for Inflammatory Bowel Disease (IBD)